LSTA

Lisata Therapeutics, Inc. (LSTA) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.9/10 — Weak · Last Updated: 2026-09-01

Revenue Growth Drivers

No reported 5-year revenue, EPS, or FCF CAGR limits evidence of repeatable compounding versus peers with documented multi-year growth trajectories.

TTM ROIC of -1.99% indicates current capital deployment is not yet generating scalable returns, reducing reinvestment capacity relative to profitable peers.

R&D intensity of 48.81% of revenue suggests heavy development spending, but absent monetization evidence it has not translated into durable revenue expansion.

Negative EV-to-sales and negative free-cash-flow yield imply the current operating model is not yet producing self-funded growth, unlike stronger peer compounders.

Market Tailwinds

No filing-based evidence shows a sustained end-market tailwind that is converting into measurable multi-year revenue acceleration versus peers.

The company’s current financial profile suggests demand is not yet large or durable enough to support efficient scaling, unlike stronger growth peers.

Without disclosed segment growth or customer expansion metrics, long-term market penetration remains unproven relative to peers with visible expansion paths.

Peer comparison is constrained by missing growth history, but available metrics do not show the structural momentum typically seen in scalable growth platforms.

Scalability Expansion

High R&D spending can support future product expansion, but current returns indicate limited near-term scalability versus peers with proven monetization.

Capex-to-revenue and capex-to-OCF both at zero suggest asset-light scaling, yet the absence of positive cash generation weakens expansion capacity.

Net debt to EBITDA of 0.65x is manageable, but leverage alone does not offset the lack of demonstrated operating scale.

The business appears capable of development spending, but peer-relative evidence of repeatable expansion, distribution leverage, or self-funded reinvestment is not yet established.

Constraints Limitations

Negative ROIC indicates structural capital inefficiency today, which caps long-term compounding unless monetization improves materially versus peers.

Missing 5-year growth and segment data limits confidence in durable scaling, making the company look less proven than peers with track records.

Negative valuation and cash-flow metrics imply the business is still constrained by weak economic conversion, reducing reinvestment flexibility.

Current evidence points to an impaired growth profile where execution must improve before long-term scalability can approach peer norms.

Overall Score

LSTA shows limited proven 10-year growth capacity because current returns are negative, monetization is unproven, and peer-relative scaling evidence is sparse.

Score Driver: Negative ROIC

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Lisata Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →